First-in-class ERG degrader is designed to treat the 40-50% of prostate cancers displaying ERG-TMPRSS2 fusions - ...

Synthetic Design Lab, a next-generation antibody-drug conjugate (ADC) company advancing its novel SYNTHBODY therapeutic platform against a range of cancer indications, emerged from stealth today with ...

Cryopreserved allogeneic Treg infusions associated with slowed disease progression and decreased plasma neurofilament level in ALS ...

MARSEILLE, France I April 22, 2025 I Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announce review of their January ...

First-in-human trial of ETX–636 to begin in Q2 2025 in patients with tumors harboring an activating PI3Kα mutation, including breast cancer ...

TAIPEI, Taiwan I April 22, 2025 I AP Biosciences, a clinical-stage biopharmaceutical company dedicated to transforming cancer therapy through development of ...

ALAMEDA, CA, USA and TAIPEI, Taiwan I April 21, 2025 I Acepodia (6976: TT) today announced the presentation of new preclinical data highlighting its ...

OSAKA, Japan I April 21, 2025 I Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) announced that it has ...

HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) (“Akeso” or the “Company”) is pleased to announce that ebdarokimab, an investigational monoclonal antibody developed by the company, has ...

PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older ...